

A&I

ANÄSTHESIOLOGIE & INTENSIVMEDIZIN

Offizielles Organ: Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e. V. (DGAI)
Berufsverband Deutscher Anästhesistinnen und Anästhesisten e. V. (BDA)

Organ: Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin e. V. (DIVI)



Sheldon-Hall syndrome

orphan**anesthesia**

a project of the German Society
of Anaesthesiology and Intensive Care Medicine

SUPPLEMENT NR. 6 | 2025

OrphanAnesthesia –

ein krankheitsübergreifendes Projekt des Wissenschaftlichen Arbeitskreises Kinderanästhesie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V.

Ziel des Projektes ist die Veröffentlichung von Handlungsempfehlungen zur anästhesiologischen Betreuung von Patientinnen und Patienten mit seltenen Erkrankungen. Damit will OrphanAnesthesia einen wichtigen Beitrag zur Erhöhung der Patientensicherheit leisten.

Patientinnen und Patienten mit seltenen Erkrankungen benötigen für verschiedene diagnostische oder therapeutische Prozeduren eine anästhesiologische Betreuung, die mit einem erhöhten Risiko für anästhesieassoziierte Komplikationen einhergehen. Weil diese Erkrankungen selten auftreten, können Anästhesistinnen und Anästhesisten damit keine Erfahrungen gesammelt haben, sodass für die Planung der Narkose die Einholung weiterer Information unerlässlich ist. Durch vorhandene spezifische Informationen kann die Inzidenz von mit der Narkose assoziierten Komplikationen gesenkt werden. Zur Verfügung stehendes Wissen schafft Sicherheit im Prozess der Patientenversorgung.

Die Handlungsempfehlungen von OrphanAnesthesia sind standardisiert und durchlaufen nach ihrer Erstellung einen Peer-Review-Prozess, an dem eine Anästhesistin bzw. ein Anästhesist sowie eine weitere Krankheitsexpertin bzw. ein weiterer Krankheitsexperte (z. B. Pädiaterin bzw. Pädiater oder Neurologin bzw. Neurologe) beteiligt sind. Das Projekt ist international ausgerichtet, sodass die Handlungsempfehlungen grundsätzlich in englischer Sprache veröffentlicht werden.

Ab Heft 5/2014 werden im monatlichen Rhythmus je zwei Handlungsempfehlungen als Supplement der A&I unter www.ai-online.info veröffentlicht. Als Bestandteil der A&I sind die Handlungsempfehlungen damit auch zitierfähig. Sonderdrucke können gegen Entgelt bestellt werden.

OrphanAnesthesia –

a project of the Scientific Working Group of Paediatric Anaesthesia of the German Society of Anaesthesiology and Intensive Care Medicine

The target of OrphanAnesthesia is the publication of anaesthesia recommendations for patients suffering from rare diseases in order to improve patients' safety. When it comes to the management of patients with rare diseases, there are only sparse evidence-based facts and even far less knowledge in the anaesthetic outcome. OrphanAnesthesia would like to merge this knowledge based on scientific publications and proven experience of specialists making it available for physicians worldwide free of charge.

All OrphanAnesthesia recommendations are standardized and need to pass a peer review process. They are being reviewed by at least one anaesthesiologist and another disease expert (e.g. paediatrician or neurologist) involved in the treatment of this group of patients.

The project OrphanAnesthesia is internationally oriented. Thus all recommendations will be published in English.

Starting with issue 5/2014, we'll publish the OrphanAnesthesia recommendations as a monthly supplement of A&I (Anästhesiologie & Intensivmedizin). Thus they can be accessed and downloaded via www.ai-online.info. As being part of the journal, the recommendations will be quotable. Reprints can be ordered for payment.

Bisher in A&I publizierte Handlungsempfehlungen finden Sie unter:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Find a survey of the recommendations published until now on:

www.ai-online.info/Orphsuppl
www.orphananesthesia.eu

Projektleitung

Dr. med. Christine Gaik, DESAIC, FESAIC

Oberärztin
Klinik für Anästhesie und Intensivtherapie
Universitätsklinikum Gießen und Marburg GmbH,
Standort Marburg
Baldingerstraße
35033 Marburg, Deutschland
E-Mail:
gaikc@med.uni-marburg.de

Priv.-Doz. Dr. med. Philipp Gude, MHBA

Geschäftsführender Oberarzt
Klinik für Anästhesiologie und Intensivmedizin
Universitätsklinikum
St. Elisabeth-Hospital
Bleichstraße 15
44787 Bochum, Deutschland
E-Mail:
philipp.gude@ruhr-uni-bochum.de

orphananesthesia

Anaesthesia recommendations for Sheldon-Hall syndrome

Disease name: Sheldon-Hall syndrome

ICD 10: Q74.3

Synonyms: Freeman-Sheldon variant, distal arthrogryposis multiplex congenita, distal arthrogryposis type 2B, distal arthrogryposis multiplex congenita type II with craniofacial abnormalities

Disease summary: Originally described as a skeletal dysplasia and later as a myopathic distal arthrogryposis, Sheldon-Hall syndrome (SHS) involved a congenital non-progressive constellation of craniofacial, hand and feet, and sometimes spinal malformations. The features in patients with SHS were less dramatic but similar to those found in patients with Freeman-Burian syndrome (FBS), with which it was often confused. Relatively little was known about SHS. While treatment for FBS and SHS was similar, distinguishing between SHS and FBS was of great therapeutic importance, with FBS being more severe, less responsive to therapy, and having an overall worse clinical outcome than SHS. The diagnostic criteria for SHS required small mouth (not microstomia), small but prominent chin, prominent nasolabial folds, neck webbing, and deformities of the distal extremities. Previous criteria included: triangular face, micrognathia, highly arched palate, attached ear lobules, down-slanting palpebral fissures, short stature, and deformities of the distal extremities. Limb malformations that were accepted in the diagnostic criteria for both FBS and SHS included two or more of the following: talipes equinovarus, metatarsus varus, vertical talus, talipes equinovalgus, calcaneovalgus, camptodactyly, ulnar deviation of wrists and fingers, overlapping fingers or toes, and hypoplastic or absent interphalangeal creases. Patients with SHS lacked a history of dysphagia and the five craniofacial features pathognomonic for FBS. Most instances of SHS were sporadic, but autosomal dominant inheritance has been established, as well. There was no apparent gender, ethnic, or geographical preference, and environmental and parental factors were not implicated in pathogenesis.

Medicine is in progress



Perhaps there is new knowledge

Every patient is unique

Perhaps the diagnosis is wrong



Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net

► **Citation:** Poling MI, Dufresne CR: Sheldon-Hall syndrome. *Anästh Intensivmed* 2025;66:S108–S118.
DOI: 10.19224/ai2025.S108

Emergency information

A	AIRWAY / ANAESTHETIC TECHNIQUE	<p>Midfacial hypoplasia may prevent mask sealing. Micrognathia, small mouth, class II malocclusion, dental crowding, highly arched hard palate, and limited cervical spine flexibility may make endotracheal intubation and use of airway adjuncts difficult. Tracheotomy may be needed for emergent or unusually challenging intubations. Hypoplastic cartilaginous landmarks may make cricothyroidotomy impossible. Spinal deformities may complicate but are unlikely to preclude epidural or spinal anaesthesia. Extremity contractures may complicate RA. Limited cervical mobility, distal extremity contractures, and small diameter/poor quality of veins complicate vascular access.</p> <p>Due to technical difficulty and possible post-operative pulmonary complications, consider avoiding pre-medication, sedation, and GA. If possible, consider local, RA, spinal, and epidural anaesthesia as alternatives when possible. If GA is needed, use recruitment manoeuvres and endotracheal suctioning before extubation to maximise lung volume and reduce the risk of atelectasis.</p>
B	BLOOD PRODUCTS (COAGULATION)	No coagulation disorder associated; no special considerations necessary.
C	CIRCULATION	No cardiopulmonary malformations, pathologies, arrhythmias, congenital heart disease, risk for heart failure, or haemodynamic issues.
D	DRUGS	Due to potential intercostal myopathy, avoid opioids and other potential respiratory depressants to reduce risk of apnoea, over-sedation, hypoventilation, and post-operative respiratory distress. There are no typical home medications. No evidence for increased risk of MH/rhabdomyolysis.
E	EQUIPMENT	Use of a small gauge vascular catheter (22 or less), paediatric spinal needle and epidural catheter, and 12 French or smaller urinary catheter are often required. Nasopharyngeal, endotracheal tubes, other airway devices, and BP cuffs typically need to be smaller, as well. Nasal and oral intubation require a flexible fibre-optic bronchoscope; if not available, blind nasal intubation may be attempted.

Disease background

Originally described as a skeletal dysplasia by Freeman and Sheldon (1938)[1] and later as a myopathic distal arthrogryposis[2-3], Sheldon-Hall syndrome (SHS; MIM: 601680) involved a congenital non-progressive constellation of craniofacial, hand and feet, and sometimes spinal malformations. Relatively little was known about SHS. The features in patients with SHS were less dramatic but similar to those found in patients with Freeman-Burian syndrome (FBS; MIM 193700). Indeed, experience indicates the features in patients with SHS were so much more moderate than those exhibited in FBS that SHS patients were far less likely to present to a craniofacial surgeon[4]. Beginning with the initial report[1] and continuing for many years, FBS and SHS were considered to represent different severities of a single pathological entity. In a review of published cases with a similar phenotype, Krakowiak et al. (1998)[5] suggested that Sheldon's patient expressed a similar but distinct phenotype from Freeman's patient[1]. The genotypical uniqueness of FBS and SHS was subsequently established[6]. Both were later renamed to reflect their divergent natural histories[4, 7-8]. While treatment for FBS and SHS was similar, distinguishing between SHS and FBS was of great therapeutic importance, with FBS being more severe, less responsive to therapy, and having an overall worse clinical outcome than SHS[7]. Furthermore, FBS was primarily a craniofacial condition, while SHS was primarily limb malformation disorder[8].

The diagnostic criteria for SHS required small mouth (not microstomia), small but prominent chin, prominent nasolabial folds, neck webbing, and deformities of the distal extremities[7]. Another criteria included: triangular face, micrognathia, highly arched palate, attached ear lobules, down-slanting palpebral fissures, short stature, and deformities of the distal extremities[9]. Limb malformations that were accepted in the diagnostic criteria[6-7] included two or more of the following: talipes equinovarus, metatarsus varus, vertical talus, talipes equinovaglus, calcaneovalgus, camptodactyly, ulnar deviation of wrists and fingers, overlapping fingers or toes, and hypoplastic or absent interphalangeal creases. Patients with SHS lacked a history of dysphagia and the five craniofacial features pathognomonic for FBS (microstomia, pursed lips or so-called whistling face, H or V- shaped chin defect, hypoplastic ala nasi, prominent nasolabial folds). Other major differential diagnoses included distal arthrogryposis types 1, 3, 7, and 8; Schwartz-Jampel syndrome; and non-syndromic distal contractures. SHS was distinguished from all other conditions by the presence of pathognomonic head and neck findings.

Most instances of SHS were sporadic, but autosomal dominant inheritance has been established, as well[7]. There was no apparent gender, ethnic, or geographical preference, and environmental and parental factors were not implicated in pathogenesis[10]. Krakowiak et al. (1997) mapped SHS to 11p15.5[11]. Sung et al. (2003) provided evidence that SHS was associated with allelic variations in the fast skeletal muscle troponin T and I (*TNNT3* and *TNNI2*; MIM 600692 and 191043) genes[12]. Tajsharghi et al. (2007) noted heterozygous allelic variation of tropomyosin beta chain (*TPM2*; MIM 190990) gene, at 9p13.2-13.1[13]. Toydemir et al. (2006) showed that allelic variations in the embryonic myosin heavy chain 3 (*MYH3*; MIM 160720) gene, at 17p-13.1, could also cause an SHS phenotype[6]. In *MYH3*, *TNNT3*, and *TPM2* allelic variation screening of patients with heritable equinovarus (N 20), vertical talus (N 5), or distal arthrogryposis type 1 (DA1) (N 6), only one *de novo* allelic variation (R63H) in *TNNT3* was found in a single patient with DA1[14]. This finding highlighted the genotype uniqueness of FBS, SHS, and DA1[14]. In investigating contracture pathogenesis, Robinson et al. (2007) showed that R174Q and R156X allelic variations on *TNNI2* gene and R63H allelic variation on *TNNT3* gene were associated with increased ATPase activity, suggesting increased calcium sensitivity and increased contractility[15].

SHS was considered to be the most common in a group of phenotypically similar entities termed distal arthrogryposes[2-3], which were thought to be the most common form of arthrogryposis syndromes. Arthrogryposis multiplex congenita is unique from the distal arthrogryposis classification of syndromes[2]. Due to the paucity of literature on anaesthesia care for patients with SHS, these clinical recommendations were based on clinical experience and a systematic

review and meta-analysis that included distal arthrogryposis syndromes and FBS[16-17], the protocol for which has been described elsewhere[18-19].

Typical surgeries

Patients with SHS frequently undergo numerous orthopaedic surgeries, because attempts at operative deformity correction may have suboptimal results and require subsequent revision. Due to wide variability of SHS presentation and the lack of research, there are a great diversity of operative approaches employed for the following reasons: ankle-foot complex contracture correction, spinal curvature correction (rod insertion and vertebral fusion), hand contracture correction, and craniofacial reconstruction. Less frequently, involvement of more proximal joints (e. g., recurrent dislocation or dysplasia of shoulders and hips, contracture of elbows, or patellar instability) is the focus of operative interventions.

Type of anaesthesia

Although most case reports describe general anaesthesia, this is not meant to imply general anaesthesia is always needed in SHS. While the anaesthetic approach is ultimately dictated by patient safety, the patient's understanding and affect regarding surgery, and technical feasibility, it may be desirable to avoid pre-medication, sedation, and general anaesthesia for appropriately selected patients with SHS[20]. Though spinal deformities occur in SHS, this typically does not preclude epidural or spinal anaesthesia, which may have far fewer syndromic-associated challenges and complications and a more favourable safety profile over sedation and general anaesthesia. Whenever possible, consider and explore local, regional, spinal, and epidural anaesthesia with patients during the pre-anaesthetic consultation. Age is not necessarily a contraindication to any particular anaesthesia modality[20]. Many adults are poor candidates for local or regional anaesthesia, and many children handle the experience very well[20]. Proper psychological preparation for patients undergoing surgery exclusively under local or regional anaesthesia does not differ substantively from any other pre-operative consent and preparation process[20].

Pre-operative testing

Anaesthetic care for patients with SHS often presents a challenge and requires considerable pre-operative planning. Patients should be evaluated well in advance of proposed procedures, if possible. The anaesthesiologist performing the evaluation should also be the anaesthesiologist assigned for the procedure. A thorough and complete history should include questions about: current medications and allergies, reactive airways disease, gastro-oesophageal reflux disease (GERD), previous acute and chronic respiratory problems, prior anaesthesia and surgeries, seizures, and any symptoms of possible central nervous system dysfunction, especially increased intracranial pressure[21]. Examination includes: vital signs, mental status, airway, spinal, neurological, and cardiopulmonary assessments[21]. It is important to explain to the patient and family possible risks and ensure questions are answered and concerns fully addressed[20-21]. Findings, concerns, and management plans must be discussed with participating surgeons[21]. The preceding pre-operative consultation and planning process may seem obvious, but unfortunately, this process does not represent a universal standard for the care of potentially high-risk patients undergoing surgery.

Some suggest that malignant hyperthermia (MH) does not have an association[22-23], with most myopathies in which anaesthetically-related hypermetabolic states resembling MH have been reported. Unless there is specific concern, an anaesthetic technique considered MH-safe

is not required for patients with SHS, but this should not preclude the use of a such a technique, if desired. An expanded metabolic panel and 12-lead electrocardiogram are appropriately included in pre-operative screening for many patients who carry a potentially higher risk for anaesthesia or sedation and prevent misinterpretation of the pre-existing status as being associated with intra-operative changes. As arterial puncture for blood gases may be infeasible, point-of-care capillary blood testing can be helpful for baseline and subsequent assessment, when available. Alternatively, pulse oxymetry on room air is a valuable non-invasive modality for assessing pulmonary gas exchange, and venous serum bicarbonate is reflective of the state of carbon dioxide exchange. Though muscle biopsy for determination of MH susceptibility can be a worthwhile assessment to make if there is some index of concern, it is not advised, due to the large muscle sample required for the *in vitro* caffeine-halothane contraction test. Genomic testing for the *RYR1* mutation is feasible, but the mutation is not associated with SHS. Notably, SHS is not associated with any cardiac muscle pathology.

Airway management

In patients with SHS, some degree of micrognathia, small mouth, class II malocclusion, dental crowding, highly arched hard palate, and limited cervical spine flexibility may make endotracheal intubation and use of airway adjuncts difficult. Although there are reports of successful direct laryngoscopy, it is likely to be difficult, if not impossible. While some providers may elect to attempt use of a Laryngeal Mask Airway (LMA) to avoid a difficult intubation, successful introduction and seating of an LMA is likely to be quite difficult or infeasible in SHS patients. A smaller LMA device than typically used for the patient's age may be necessary. LMA devices are not judged to be a reasonable airway management method for patients presenting with more severe features. The possibility for GERD in this population may also modify intubation options[21], but appropriate fasting times and commonly prescribed GERD medical prophylaxis may reduce the risk.

Where available, a flexible fibre-optic bronchoscope guided technique is advised for non-emergent nasal or oral intubation. In institutions with limited facilities, blind nasal intubation may be attempted but risks airway trauma. These patients are most safely cared for in hospitals with the full range of airway equipment that may be needed. Patients can spontaneously ventilate with positive airway pressure support delivered through a soft nasopharyngeal airway in one nare, while fibre-optically guided intubation is performed through the other nare or the mouth. Mask ventilation may be possible, as well, but patients must be evaluated for adequate sealing pre-operatively, given the anatomical challenges involved. If an LMA can be introduced, fibre-optic intubation can be performed through the LMA. Tracheotomy may be needed for emergent or unusually challenging intubations but may be technically challenging. Surgical back up should be arranged for the most difficult airways. Airway management can be performed by spontaneous breathing of an inhaled agent or with intravenous infusion of propofol or dexmedetomidine, alone or in combination.

Transfusion or administration of blood products

No reports in the literature or known clinical experience indicate any unusual problems or needed precaution for patients with SHS needing transfusion or administration of any blood components. Distal extremity contractures and the consequent poor quality of veins may make establishing peripheral intravenous access challenging in many patients with SHS, and limited cervical mobility complicates neck vein access. Use of a small gauge catheter, 22 or less is often required. Need for the use of a small gauge vascular catheter may impair transfusion, intravenous hydration, medication administration, and blood draw efforts. With increased use of ultrasound assisted peripheral vein cannulation, central line placement has a diminished role in providing vascular access for these patients but still may be necessary more frequently.

Anticoagulation

While many patients have reduced pre-operative mobility and, therefore, are at a somewhat higher pre-operative thrombogenic risk, no reports in the literature or known clinical experience indicate any disorder of coagulation associated with SHS.

Patient transportation and positioning

Carefully evaluate patients pre-operatively to assess the extent of contractures. Any range of motion limitations found should be discussed with surgeons to plan the best positioning for the patient during surgery. If possible, positioning before induction of anaesthesia is recommended but may not be feasible. Patients should always be placed in a position of respiratory comfort, with avoidance of unnatural mobilisation under anaesthesia, kept warm, and provided with generous padding to avoid pressure points. Use of padded dressings is recommended for areas at risk for pressure injury (sacrum if supine; breasts and iliac crests if prone). Thin patients and those with extended inpatient confinement are at higher risk for loss of skin integrity. Patients with skin complications should be seen by a plastic surgeon. Active forced air heating systems should be used to maintain patient normothermia during anaesthesia and surgery, as many of these patients have reduced adipose tissue and are at increased risk of hypothermia.

Interactions of chronic disease and anaesthesia medications

There are no syndrome-specific chronic medications for patients with SHS, and there is no syndrome-specific treatment. Therapeutic interventions focus on improving functional outcomes. There is no cure, though SHS is believed to be non-progressive.

Anaesthetic procedure

The evidence base does not support an association between MH and SHS[22-23]. Nonetheless, in some clinical situations it may be desirable to avoid MH-triggering agents, any of which are safely used in patients with SHS, though some are used more extensively. Oral midazolam is routinely used for pre-medication, and intravenous midazolam is often used for mild procedural sedation. If an MH-safe technique is preferred, induction of general anaesthesia is safely achieved with nitrous oxide, which is not a volatile MH-triggering gas. If maintenance of spontaneous respiration is essential, nitrous oxide is used in conjunction with ketamine to achieve and maintain surgical anaesthesia. If vascular access is established before induction, propofol is frequently used for induction and maintenance of surgical anaesthesia. Intravenous infusion of either propofol or dexmedetomidine or both can be used to establish moderate sedation, with preservation of spontaneous ventilation for airway management and surgical anaesthesia. Spontaneous ventilation also can be maintained with nitrous oxide, ketamine, propofol, dexmedetomidine, or low-dose infusion of short-acting opioids, such as remifentanyl.

Lidocaine with or without epinephrine for local anaesthesia or bupivacaine (0.25 – 0.5%) or ropivacaine for local anaesthesia, spinal, or epidural anaesthesia may be used. If performing spinal or epidural anaesthesia, a paediatric size needle and catheter is used, even for adults, as most patients with SHS are small. When using lidocaine or bupivacaine for anaesthesia without adjuvants, no special precautions are required, except for precautions related to the actual operative intervention, itself. Peripheral nerve blocks, either single bolus injection or with catheter placement, may be used for extremity surgery and post-operatively for analgesia.

Patient monitoring

While standard modern anaesthesia monitoring modalities (e.g., heart rate, oxygen saturation, blood pressure, end tidal carbon dioxide (ETCO₂), respiratory rate and depth, and temperature) are sufficient, vigilance is needed for monitoring in patients with SHS. Muscle rigidity or relaxation is not a reliable indicator of anaesthesia depth or neuromuscular blockade effectiveness, as syndromically affected muscles, especially those exhibiting overt contracture, are unaffected by anaesthesia and muscle relaxants. Oxygen saturation and ETCO₂ must be closely observed, especially if obstructive sleep apnoea or intercostal muscle pathology causing restrictive pulmonary disease is suspected. As clip sensors may not fit well, flexible adhesive oxygen saturation sensors are preferred and readily available in all institutions. They are applied circumferentially and fit any digit in the largest or smallest of patients. If a urinary catheter is used for monitoring, during a long surgery, or when epidural anaesthesia-analgesia is used, a paediatric size is typically chosen, even for adults, as most patients with SHS are small. If present, the character of dysphasia caused by orofacial anatomical abnormalities and muscle contractures should be documented before administration of any medication is noted to reduce potential mischaracterisation of dysphasia during pre-medication, sedation, or monitored anaesthesia when spoken patient responses are required.

Complications

As noted previously, evidence suggests SHS may not have an association with MH[22-23]; however, the following have traditionally been considered potential complications of general anaesthesia or sedation in patients with SHS: hyperpyrexia without the malignant hyperthermia triad, malignant hyperthermia, and neuroleptic malignant syndrome (hypermetabolic syndrome similar to malignant hyperthermia). Other complications that are more likely to present include, rhabdomyolysis without hyperpyrexia, challenging peripheral vascular access, impaired operative access due to ineffectiveness of neuromuscular blockade, and oro-tracheal intubation difficulty due to anatomic abnormalities. Airway abnormalities leading to difficult intubation includes: small mouth, cervical spine immobility, and stiffness of the orofacial musculature. While primarily reported in FBS, post-operative or post-sedation pneumonia may be caused by hypoventilation (atelectasis). In contrast to FBS, dysphagia, with an attendant elevated aspiration risk, is not a finding in SHS, and meticulous anaesthetic care usually prevents aspiration. If present, spinal deformities complicate epidural and spinal anaesthesia but rarely preclude it.

Post-operative care

In some patients, intercostal muscles are unable to provide adequate changes in intrathoracic pressure due to fibrous replacement. If intercostal myopathy is present, opioids and other potential respiratory depressants potentiate the risk for apnoea, over-sedation, and hypoventilation and may lead to post-operative respiratory distress. Non-steroidal anti-inflammatory medications, enhanced recovery after anaesthesia and surgery protocols, and continuation of regional or epidural catheter techniques for post-operative analgesia provide the best pain control modalities for patients with SHS. Most patients are observed in the intensive or intermediate care unit for at least some time, especially after major surgery.

Disease-related acute problems and effect on anaesthesia and recovery

www.orphananesthesia.eu

7

Although primarily reported in FBS, the possibility for acute consequences of potential decreased thoracic cage compliance from non-functioning intercostal muscles in patients with SHS must be considered. If intercostal muscle pathology is suspected, it predisposes the patient to lower respiratory infections, with prolonged recovery. Aggressive antibiotic use and guaifenesin are warranted in the presence of positive physical examination findings of râles, rhonchi, wheezes, and pyrexia. In patients with intercostal muscle pathology, chest radiographs often are uninterpretable, with poor lung inflation due to decreased forced vital capacity and poor cough. In the advent of lower respiratory infection, sputum culture often is non-diagnostic, as many of these patients do not have adequate ability to cough. These patients require meticulous respiratory therapy in the post-operative period, which may include incentive spirometry, chest physiotherapy, with or without the use of a cough assist machine, and implementation of BiLevel Positive Airway Pressure, if airway obstruction or hypoventilation occur. If a culture is required, consider bronchoscopy to obtain a clean specimen. If general anaesthesia with intubation is necessary, the anaesthesiologist should use recruitment manoeuvres and endotracheal suctioning prior to exubation to maximise lung volume and reduce the risk of atelectasis.

Special settings or types of anaesthesia

The general principles for the anaesthetic care of patients with SHS previously described apply with proper balancing of risks and benefits, to all types and settings of anaesthesia, including obstetric, ambulatory, or emergent.

References

- Freeman EA, Sheldon JH. Cranio-carpo-tarsal dystrophy: undescribed congenital malformation. *Arch Dis Child*. 1938;13:277-283. DOI: 10.1136/adc.13.75.277
- Hall JG, Reed SD, Greene G. The distal arthrogryposes: delineation of new entities—review and nosologic discussion. *Am J Med Genet*. 1982;11(2):185-239. DOI: 10.1002/ajmg.1320110208
- Bamshad M, Jorde LB, Carey JC. A revised and extended classification of the distal arthrogryposes. *Am J Med Genet*. 1996;65(4):277-81. DOI: 10.1002/(SICI)1096-8628(19961111)65:4<277::AID-AJMG6>3.0.CO;2-M
- Poling MI, Dufresne CR. Revisiting the many names of Freeman-Sheldon syndrome. *J Craniofac Surg*. In Press. DOI: 10.1097/SCS.0000000000004802
- Krakowiak PA, Bohnsack JF, Carey JC, Bamshad M. Clinical analysis of a variant of Freeman-Sheldon syndrome (DA2B). *J Med Genet*. 1998;26(1):93-8. PMID: 9508073
- Toydemir RM, Rutherford A, Whitby FG, Jorde LB, Carey JC, Bamshad MJ. Mutations in embryonic myosin heavy chain (*MYH3*) cause Freeman-Sheldon syndrome and Sheldon-Hall syndrome. *Nat Genet*. 2006;38(5):561-5. DOI: 10.1038/ng1775
- Stevenson DA, Carey JC, Palumbos J, Rutherford A, Dolcourt J, and Bamshad MJ. Clinical characteristics and natural history of Freeman-Sheldon syndrome. *Pediatrics*. 2006;117(3):754-762. DOI: 10.1542/peds.2005-1219
- Poling MI, Dufresne CR. Head first, not feet first: Freeman-Sheldon syndrome as primarily a craniofacial condition. *Cleft Palate-Craniofac J*. 2018;55(5):787-788. doi: 10.1177/1055665617753482
- Toydemir RM, Bamshad MJ. Sheldon-Hall syndrome. *Orphanet J Rare Dis*. 2009;4:11. doi:10.1186/1750-1172-4-11
- McKusick VA. *Online mendelian inheritance in man, OMIM™*. Johns Hopkins University, Baltimore, MD. MIM Number: 601680. Retrieved: 30 April 2017. URL: <http://omim.org>
- Krakowiak PA, O'Quinn JR, Bohnsack JF, Watkins WS, Carey JC, Jorde LB, Bamshad M. A variant of Freeman-Sheldon syndrome maps to 11p15.5-pter. *Am J Hum Genet*. 1997;60:426-432. PMID: 9012416
- Sung SS, Brassington AME, Krakowiak PA, Carey JC, Jorde LB, Bamshad MJ. Mutations in *TNNT3* cause multiple congenital contractures: a second locus for distal arthrogryposis type 2B. *Am J Hum Genet*. 2003;73:212-214. DOI: 10.1086/376418
- Tajsharghi H, Kimber E, Holmgren D, Tulinius M, Oldfors A. Distal arthrogryposis and muscle weakness associated with a betatropomyosin mutation. *Neurology*. 2007;68(10):772-775. DOI: 10.1212/01.wnl.0000256339.40667.fb
- Gurnett CA, Alaei F, Desruisseau D, Boehm S, Dobbs MB. Skeletal muscle contractile gene (*TNNT3*, *MYH3*, *TPM2*) mutations not found in vertical talus or clubfoot. *Clin Orthop Relat Res*. 2009;467(5):1195-200. DOI: 10.1007/s11999-008-0694-5
- Robinson P, Lipscomb S, Preston LC, Altin E, Watkins H, Ashley CC, Redwood CS. Mutations in fast skeletal troponin I, troponin T, and beta-tropomyosin that cause distal arthrogryposis all increase contractile function. *FASEB J*. 2007;21:896-905. DOI: 10.1096/fj.06-6899com
- Poling MI, Dufresne CR, Chamberlain RL. Findings, Phenotypes, Diagnostic Accuracy, and Treatment in Freeman-Burian Syndrome. *J Craniofac Surg*. 2020;31(4):1063-1069. DOI: 10.1097/SCS.0000000000006299
- Poling MI, Dufresne CR, Portillo AL. Identification and Recent Approaches for Evaluation, Operative Counseling, and Management in Patients With Freeman-Burian Syndrome: Principles for Global Treatment. *J Craniofac Surg*. 2019;30(8):2502-2508. DOI: 10.1097/SCS.0000000000005968
- Poling MI, Morales Corado JA, Chamberlain RL. Findings, phenotypes, and outcomes in Freeman-Sheldon and Sheldon-Hall syndromes, and distal arthrogryposis types 1 and 3: protocol for systematic review and patient-level data meta-analysis. *Syst Rev*. 2017;6:46. DOI: 10.1186/s13643-017-0444-4
- Poling MI, Morales Corado JA, Chamberlain RL. Findings, Phenotypes, and Outcomes in Freeman-Sheldon and Sheldon-Hall syndromes, and Distal Arthrogryposis Types 1 and 3: Protocol for Systematic Review and Patient-Level Data Meta-Analysis. *PROSPERO*. 2015. Accession number: CRD42015024740. <https://www.crd.york.ac.uk/PROSPERO/view/CRD42015024740>

20. Portillo AL, Poling MI, McCormick RJ. Surgical approach, findings, and 8-year follow-up in a 21-year-old woman with Freeman-Sheldon syndrome presenting with blepharophimosis causing near-complete visual obstruction. *J Craniofac Surg.* 2016;27(5):1273-1276. DOI: 10.1097/SCS.0000000000002781
21. Deshpande J, Maxwell LG. Chapter 9: Anesthetic management. In: Dufesne CR, Carson BS, Zinreich SJ, eds. *Complex craniofacial problems: a guide to analysis and treatment.* New York: Churchill Livingstone, 1992.
22. Benca J, Hogan K. Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options. *Anesth Analg.* 2009;109:1049-1053. DOI: 10.1213/ane.0b013e3181adca28
23. Gleich SJ, Tien M, Schroeder DR, Hanson AC, Flick R, Nemergut ME. Anesthetic outcomes of children with arthrogryposis syndromes: no evidence of hyperthermia *Anesth Analg.* 2017;124:908-914. DOI: 10.1213/ANE.0000000000001822

Date last modified (updated): April 2025

This recommendation was prepared by:

Authors

Mikaela I Poling, Research Assistant, Office of Craig R Dufresne, MD, PC, Fairfax, VA, USA

Craig R Dufresne, Plastic Surgeon, Private Practice, Fairfax, VA, USA

Disclosure(s) The authors have no financial or other competing interest to disclose. This recommendation was unfunded.

This recommendation was reviewed by:

Reviewers

Lynne G Maxwell, Emeritus Professor CE of Anesthesiology and Critical Care; Diversity Search Advisor, Department of Anesthesiology and Critical Care, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

Robert B Mesrobian, Pediatric Anesthesiologist, Department of Anesthesiology, Inova Fairfax Hospital, Falls Church, VA, USA

Editorial Review

Tino Münster, Department of anaesthesiology and intensive care medicine, Hospital Barmherzige Brüder, Regensburg, Germany

Disclosure(s) The reviewers have no financial or other competing interest to disclose.

Herausgeber



DGAI

Deutsche Gesellschaft
für Anästhesiologie und
Intensivmedizin e. V.
Präsident: Prof. Dr. G. Marx,
Aachen



BDA

Berufsverband Deutscher
Anästhesistinnen und
Anästhesisten e. V.
Präsidentin: Prof. Dr.
G. Beck, Mannheim

Schriftleitung

Präsident/in der Herausgeberverbände
Gesamtschriftleiter/Editor-in-Chief:
Prof. Dr. Dr. Kai Zacharowski,
ML FRCA FESAIC, Frankfurt
Stellvertretender Gesamtschriftleiter/
Deputy Editor:
Prof. Dr. T. Volk, Homburg/Saar
CME-Schriftleiter/CME-Editor:
Prof. Dr. W. Zink, Ludwigshafen

Redaktionskomitee/Editorial Board

Priv.-Doz. Dr. E. Adam, Frankfurt
Prof. Dr. M. Adamzik, Bochum
Dr. J. Aulenkamp, Essen
Prof. Dr. G. Beck, Mannheim
Prof. Dr. T. Brenner, Essen
Prof. Dr. A. Brinkmann, Heidenheim
Prof. Dr. M. Coburn, Bonn
Prof. Dr. S.M. Coldewey, Jena
Prof. Dr. V. von Dossow, Bad Oeynhausen
Prof. Dr. B. Ellger, Dortmund
Prof. Dr. K. Engelhard, Mainz
Prof. Dr. M. Fischer, Göttingen
Prof. Dr. D. Fries, Innsbruck
Prof. Dr. J.-T. Gräsner, Kiel
Prof. Dr. K. Hahnenkamp, Greifswald
Prof. Dr. A.R. Heller, Augsburg
Prof. Dr. B. Jungwirth, Ulm
Prof. Dr. T. Loop, Freiburg
Prof. Dr. K. Meissner, Göttingen
Prof. Dr. W. Meißner, Jena
Prof. Dr. P. Meybohm, Würzburg
Prof. Dr. T. Müller-Wolff, Ludwigsburg
Prof. Dr. H. Mutlak, Offenbach
Prof. Dr. C. Nau, Lübeck
Priv.-Doz. Dr. V. Neef, Frankfurt
Prof. Dr. B. O'Brien, Berlin
Dr. B. Oehler, Heidelberg
Prof. Dr. S.G. Sakka, Koblenz
Prof. Dr. M. Sander, Gießen
Prof. Dr. B. Saugel, Hamburg
Prof. Dr. S. Schäfer, Oldenburg
Priv.-Doz. Dr. H. Schöchl, Salzburg
Prof. Dr. A. Steinbicker, Köln
Dr. M.T. Völker, Leipzig
Prof. Dr. N.-M. Wagner, Würzburg
Prof. Dr. F. Wappler, Köln
Prof. Dr. M. Weigand, Heidelberg

Redaktion/Editorial Staff

Korrespondenzadresse:
Neuwieder Straße 9 | 90411 Nürnberg |
Deutschland | Tel.: 0911 9337812
E-Mail: redaktion@ai-online.info

Verlag & Druckerei

Aktiv Druck & Verlag GmbH

An der Lohwiese 36 |
97500 Ebelsbach | Deutschland
www.aktiv-druck.de



Geschäftsführung

Wolfgang Schröder | Jan Schröder |
Nadja Schwarz
Tel.: 09522 943560 | Fax: 09522 943567
E-Mail: info@aktiv-druck.de

Anzeigen | Vertrieb

Pia Müller | Robert Kux
Tel.: 09522 943570 | Fax: 09522 943577
E-Mail: anzeigen@aktiv-druck.de

Verlagsrepräsentanz

Jürgen Distler
Neuwieder Straße 9 | 90411 Nürnberg
Tel.: 0171 9432534
E-Mail: jdistler@bda-ev.de

Herstellung | Gestaltung

Pia Müller | Robert Kux | Stefanie Triebert
Tel.: 09522 943570 | Fax: 09522 943577
E-Mail: ai@aktiv-druck.de

Titelbild

Gestaltung: Roland Mehl
3D Arts GmbH
Landgrabenstraße 121 | 90459 Nürnberg
E-Mail: rmehl@3darts.de
www.3darts.de

Erscheinungsweise 2025

Der 66. Jahrgang erscheint jeweils zum
Monatsanfang, Heft 7/8 als Doppelausgabe.

Bezugspreise (inkl. Versandkosten):

• Einzelhefte	30,- €
• Jahresabonnement:	
Europa (ohne Schweiz)	258,- €
(inkl. 7 % MwSt.)	
Schweiz	266,- €
Rest der Welt	241,- €

Mitarbeiter aus Pflege, Labor, Studenten und Auszubildende (bei Vorlage eines entsprechenden Nachweises)

Europa (ohne Schweiz)	94,- €
(inkl. 7 % MwSt.)	
Schweiz	90,- €
Rest der Welt	94,- €

**Für Mitglieder der DGAI und/oder
des BDA ist der Bezug der Zeitschrift
im Mitgliedsbeitrag enthalten.**

Allgemeine Geschäfts- und Liefer- bedingungen

Die allgemeinen Geschäfts- und Liefer-
bedingungen entnehmen Sie bitte dem Im-
pressum auf www.ai-online.info

Indexed in **CINAHL**; **Current Contents®/Clinical Medicine**; **EBSCO**; **EMBASE/Excerpta Medica**; **Medical Documentation Service**; **Research Alert**;
Sci Search; **Scopus**; **SUBIS Current Awareness in Biomedicine**; **VINITI**;
Russian Academy of Science.

Nachdruck | Urheberrecht

Die veröffentlichten Beiträge sind urheberrechtlich geschützt. Jegliche Art von Vervielfältigungen – sei es auf mechanischem, digitalem oder sonst möglichem Wege – bleibt vorbehalten. Die Aktiv Druck & Verlags GmbH ist allein autorisiert, Rechte zu vergeben und Sonderdrucke für gewerbliche Zwecke, gleich in welcher Sprache, herzustellen. Anfragen hierzu sind nur an den Verlag zu richten. Jede im Bereich eines gewerblichen Unternehmens zulässig hergestellte oder benutzte Kopie dient gewerblichen Zwecken gem. § 54 (2) UrhG. Die Wiedergabe von Gebrauchsnamen, Handelsnamen, Warenbezeichnungen usw. in dieser Zeitschrift berechtigt auch ohne besondere Kennzeichnung nicht zu der Annahme, dass solche Namen im Sinne der Warenzeichen- und Markenschutz-Gesetzgebung als frei zu betrachten wären und daher von jedermann benutzt werden dürften.

Wichtiger Hinweis

Für Angaben über Dosierungsanweisungen und Applikationsformen kann vom Verlag und den Herausgebern keine Gewähr übernommen werden. Derartige Angaben müssen vom jeweiligen Anwender im Einzelfall anhand anderer Literaturstellen auf ihre Richtigkeit überprüft werden. Gleiches gilt für berufs- und verbandspolitische Stellungnahmen und Empfehlungen.

Die Beiträge aus der A&I
finden Sie online unter:
www.ai-online.info

CONTACT US

Please do not hesitate to contact us. We will be glad to answer and provide further information to you at any time.

.....
Name

.....
First Name

.....
Department / Hospital

.....
Place

.....
Telephone

.....
E-Mail

.....
Date / Signature

Please contact me for further information

☐

I would like to participate in the project

☐

ADDRESS

German Society of Anaesthesiology and
Intensive Care Medicine
Neuwieder Straße 9 | 90411 Nuremberg | Germany
Tel.: +49-911-933780
Email: info@orphananesthesia.eu